Why the study?
Modulation of cardiac inflammation is an attractive target for heart failure treatment because inflammation plays dual beneficial and detrimental roles in pathogenesis and regeneration.
Despite the critical role of inflammation in heart failure progression and post-infarction remodeling, broad anti-inflammatory therapies have largely failed in clinical trials, highlighting the need for more targeted immunomodulatory approaches.
Anti-inflammatory therapies should not yet change heart failure practice; leaves open whether targeted immunomodulation will prove effective.
Inflammation plays a central role in the development of heart failure, especially in heart failure with preserved ejection fraction (HFpEF). Furthermore, the inflammatory response enables the induction of regenerative processes following acute myocardial injury. Recent studies in humans and animals have greatly advanced our understanding of the underlying mechanisms behind these adaptations. Importantly, inflammation can have both beneficial and detrimental effects, dependent on its extent, localization, and duration. Therefore, modulation of cardiac inflammation has been suggested as an attractive target for the treatment of heart failure, which has been investigated in numerous clinical trials. This review discusses key inflammatory mechanisms contributing to the pathogenesis of heart failure and their potential impact as therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Riehle et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: